McQuaid v. Burlington County Memorial Hosp.

Decision Date12 May 1986
Citation515 A.2d 796,212 N.J.Super. 472
PartiesElizabeth McQUAID, Executrix of the Estate of Joseph T. McQuaid, Deceased, Plaintiff-Appellant, v. BURLINGTON COUNTY MEMORIAL HOSPITAL, Herbert M. Epstein, M.D., Elmer Pasimio, M.D., Ruth L. Rizzo, M.D. and American Home Products Corporation, Ayerst Laboratories, Defendants-Respondents.
CourtNew Jersey Superior Court — Appellate Division

Gary D. Ginsberg, Cherry Hill, for plaintiff-appellant (Nathan A. Friedman, atty.; Gary D. Ginsberg, on the brief).

John R. Orlovsky, Toms River, for defendants-respondents Herbert M. Epstein, M.D. and Elmer Pasimio, M.D. (Orlovsky, Grasso & Orlovsky, attys.; John R. Orlovsky on the brief).

John H. Osorio, for defendant-respondent Ruth L. Rizzo, M.D. (Montano, Summers, Mullen, Manuel & Owens, attys.; Arthur Montano, Westmont, on the brief).

Anita Hotchkiss, Morristown, for defendant-respondent Ayerst Laboratories (Porzio, Bromberg & Newman, attys.; Anita Hotchkiss, of counsel and on the brief).

Before Judges DREIER, BILDER and GRUCCIO.

BILDER, J.A.D.

This is a medical malpractice, drug product liability action arising out of the use of halothane anesthesia during the performance of an operation on plaintiff's decedent. Named as defendants were the decedent's surgeon, Dr. Epstein; the anesthesiologist, Dr. Pasimio; Dr. Rizzo, a resident who took the decedent's pre-surgical history; Ayerst Laboratories, the manufacturer of the halothane; and Burlington County Memorial Hospital. The claim against the hospital was dismissed after openings. Plaintiff does not appeal this ruling.

In general, plaintiff contended that her decedent's death was caused by his hypersensitivity to halothane; that the doctors were negligent in administering it without consulting records of prior hospitalizations which would have alerted them to his sensitivity to the drug; and that the manufacturer failed to provide sufficient warnings of the danger.

Following a 14-day trial, in answers to special interrogatories, the jury found that (a) decedent's death was caused by the halothane but (b) Ayerst had not failed to give adequate warnings, and (c) none of the doctors were negligent. Plaintiff appeals from the resultant verdict of no cause for action and the denial of her motion for a new trial. In her brief on appeal she makes the following contentions:

POINT ONE: THE JURY'S VERDICT THAT AYERST LABORATORIES DID NOT FAIL TO GIVE ADEQUATE WARNINGS TO THE MEDICAL PROFESSION CONCERNING THE INHERENT RISKS OF HALOTHANE WAS AGAINST THE WEIGHT OF THE EVIDENCE AND A GROSS MISCARRIAGE OF JUSTICE.

POINT TWO: DR. JEWELL'S TESTIMONY THAT AYERST LABORATORIES CHANGED THE CONTENTS OF ITS PACKAGE INSERT BECAUSE OF A REQUEST BY THE FDA WAS IRRELEVANT AND SEVERELY PREJUDICIAL AND SHOULD NOT HAVE BEEN ALLOWED.

POINT THREE: APPELLANT IS ENTITLED TO A NEW TRIAL AS TO ALL DEFENDANTS BECAUSE OF THE PREJUDICIAL EFFECT THAT THE FDA TESTIMONY HAD CONCERNING ALL DEFENDANTS.

POINT FOUR: THE APPELLANT WAS UNDULY PREJUDICED BY THE TRIAL COURT'S REFUSAL TO ALLOW THE APPELLANT TO READ INTO THE EVIDENCE PORTIONS OF THE DEPOSITION OF DEFENDANT DR. PASIMIO'S EXPERT WITNESS, DR. SCOTT.

POINT FIVE: THE TRIAL COURT ERRED IN FAILING TO GIVE AN ADVERSE INFERENCE CHARGE BASED ON THE NON-APPEARANCE OF DR. SCOTT.

POINT SIX: THE COURT'S REFUSAL TO ALLOW APPELLANT'S EXPERT TO CITE THE MANY ARTICLES AND TEXTS HE HAD READ CONCERNING HALOTHANE ANESTHESIA WAS REVERSIBLE ERROR.

POINT SEVEN: THE JURY'S VERDICT THAT DR. PASIMIO WAS NOT NEGLIGENT WAS SHOCKING IN THE FACE OF THE TESTIMONY AT TRIAL AND WAS CLEARLY AND CONVINCINGLY A MISCARRIAGE OF JUSTICE UNDER THE LAW.

Basic to plaintiff's appeal are two arguments. First, that the verdicts were against the weight of the evidence; second, that improper evidential rulings deprived her of a fair trial. The contentions...

To continue reading

Request your trial
6 cases
  • Shackil v. Lederle Laboratories
    • United States
    • New Jersey Superior Court — Appellate Division
    • August 12, 1987
    ...907, 93 L.Ed.2d 857 (1987) (involving adequacy of cigarette labelling and advertising); McQuaid v. Burlington County Memorial Hospital, 212 N.J.Super. 472, 475-476, 515 A.2d 796 (App.Div.1986) (raising the question whether FDA action dictating the warning to be given "does not indeed provid......
  • Feldman v. Lederle Laboratories
    • United States
    • New Jersey Supreme Court
    • June 10, 1993
    ...of whether reasonable care requires warnings in addition to what is called for by statute); McQuaid v. Burlington County Memorial Hospital, 212 N.J.Super. 472, 475-76, 515 A.2d 796 (App.Div.1986) (stating that although manufacturer's compliance with FDA request to remove part of warning lab......
  • Feldman v. Lederle Laboratories, a Div. of American Cyanamid Co.
    • United States
    • New Jersey Superior Court — Appellate Division
    • July 13, 1989
    ...616, 634, 530 A.2d 1287 (App.Div.1987), certif. granted 109 N.J. 519, 520, 537 A.2d 1304 (1987). See also, McQuaid v. Burlington County Memorial Hosp., 212 N.J.Super. 472, 476 (n. 1), 515 A.2d 796 Plaintiff argues that, at the second trial of this matter, Lederle's proofs were "no more comp......
  • Bradford v. Kupper Associates
    • United States
    • New Jersey Superior Court — Appellate Division
    • August 10, 1995
    ...an expert who was earlier deposed "does not normally justify an adverse inference charge." McQuaid v. Burlington County Memorial Hospital, 212 N.J.Super. 472, 476, 515 A.2d 796 (App.Div.1986). See also Anderson, supra, 158 N.J.Super. at 395, 386 A.2d Plaintiffs argue that the trial judge ab......
  • Request a trial to view additional results

VLEX uses login cookies to provide you with a better browsing experience. If you click on 'Accept' or continue browsing this site we consider that you accept our cookie policy. ACCEPT